DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board April 4, 2019 • 5:30 AM EDT
DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083 April 3, 2019 • 5:30 AM EDT
DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM February 20, 2019 • 5:30 AM EST
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results February 12, 2019 • 5:30 AM EST
DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting November 20, 2018 • 5:30 AM EST
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results November 14, 2018 • 5:30 AM EST
DelMar Announces Further Validation of the Mechanism of Action of VAL-083 October 10, 2018 • 5:30 AM EDT
DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results September 24, 2018 • 6:00 AM EDT
DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor September 4, 2018 • 5:30 AM EDT